Cannabinoids

The cannabinoids cannabidiol (CBD) and cannabidivarin (CBDV) showed antifungal activity in both in vivo tests and in vitro wound models.

The study also identified a new cannabinoid in the plant, named cannabielsoxa.

Here, we bring you our top four recent articles covering the cost of compliance in the industry, the role of lighting in indoor cultivation, and research involving cannabis ointment and cannabis-coated pillowcases.

The ointment containing CBD and CBG was evaluated for its effect on improvements in symptoms after an eight week period.

GVB Biopharma announced their new CBT Isolate product.

This survey assesses consumer awareness, usage patterns, and safety concerns with results indicating that cannabidiol (CBD), Δ8-tetrahydrocannabinol (Δ8-THC), and cannabinol (CBN) are the most frequently used cannabinoids, with vapes and edibles being the preferred methods of consumption.

Nanoemulsion technology is poised to play a pivotal role in the future of cannabinoid delivery as it helps address challenges related to the solubility, bioavailability, and stability of cannabinoids.

The December webinar from Healer featured several studies on various conditions treated with medical cannabis.

Here, Scott Mazza, Founder of Vitality CBD, provides an overview on the potential benefits of minor cannabinoids including cannabinol (CBN) and cannabingerol (CBG).

This article examines what rescheduling cannabis would involve, the implications for various sectors, and the potential roadblocks that could arise along the way.

The bill regulates the sale and distribution of products containing synthetic THC, though some challenges remain to be resolved.

Products containing Delta-8 THC may be leading to an increase in calls to poison control centers, according to a recent study.

A recent study targeting mild to moderate anxiety disorders showed that oral CBD can be a safe, effective treatment option.

This article provides an analysis of current regulations and proposed changes that could impact the hemp industry.

Missouri’s Department of Health and Senior Services is on track to “embargo and condemn” products that contain intoxicating cannabinoids starting September 1, 2024 in accordance to an executive order signed by the state’s governor, Michael L. Parsons.

This month’s Healer webinar provided a deep dive into several studies on cannabis for various conditions.

This presentation provided a comprehensive overview of cannabigerol (CBG), highlighting two studies on its effects on anxiety, stress, and pain.

The discussion surrounding intoxicating the manufacture and sale of hemp-derived cannabinoids continues with more proposals and challenges.

This article will cover what the differences are between hemp and cannabis, the products that are on the market today, and why it is important to know where your product is coming from.

This review highlights an in-silico assessment of the binding interactions of pro-drug moiety analogs and an importance in identifying potential issues that would need further testing to ensure safety for consumers such as the hERG values which are pertinent in the pharmaceutical fields in whether or not drugs can be safe to use.

This month’s Healer webinar provided a deep dive into six studies on cannabis for various conditions.

The cannabis industry continues to demand high purity cannabis extracts at a low cost. Here, we investigate the opportunities and challenges as manufacturers implement automation and scaling up production.

As markets mature, manufacturing terpene blends have become a new art form and a differentiating factor for potential therapeutic applications. Here, we dive deeper into the insights of terpene formulation considerations.

Two cannabinoids were shown to help with both pain relief and healing of fractures.

Both the Senate and the House have drafted bills restricting the sale of hemp-derived products.

A bill to ban unregulated tetrahydrocannabinol (THC) products was approved by a House committee.

On January 31, 2024, the GMP Collective presented the seventeenth episode in their ongoing webinar series, When Things Go Wrong.

A recent study explored cannabinoids as an alternative treatment for neuropathic pain from spinal cord injuries.

A recent study examined adult use of four cannabinoids within the past year.

A study involving cannabigerol (CBG) injections in mice tested the effectiveness in pain reduction.